NRAS and neoplasm: We confirmed substantial NRAS gene amplification in the CUTO44 cell line using NRAS FISH probes and observed an average of 21 copies of NRAS per cell and an NRAS/CEP1 ratio of 3.4, and NRAS amplification was not present in the patient tumor sample biopsied prior to crizotinib therapy (Fig. 3c).